ALCON INC ALC

Healthcare SIC 3851 - Ophthalmic Goods NAICS Manufacturing › Miscellaneous Manufacturing › Medical Equipment and Supplies Manufacturing › Ophthalmic Goods Manufacturing derived NYSE

Last close —
Market cap —
52-week range — - —

No price or market cap here: this company files no 10-K, so the only share count SEC publishes for it counts its ordinary shares in its home market, while its US listing is a depositary receipt standing for some number of them. That number is in no filing, so a price multiplied by that count is not this company's value and is not shown. The financial statements below are as filed.

Valuation FY2025 figures against the last close

P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS—

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $10.40B$9.91B$9.46B$8.72B$8.29B$6.83B$7.51B$7.15B$6.79B—
Operating income $1.36B$1.41B$1.04B$672.0M$580.0M-$482.0M-$187.0M-$248.0M-$77.0M—
Net income $980.0M$1.02B$974.0M$335.0M$376.0M-$531.0M-$656.0M-$227.0M$256.0M—

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets $31.55B$30.35B$29.61B$29.16B$28.00B$27.60B$27.66B$27.06B——
Total equity $22.04B$21.55B$20.62B$19.68B$19.26B$18.82B$19.30B$22.64B$23.03B$23.01B

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001167379-26-000014.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -5B 0 5B 10B 15B Revenue, FY2017: 6.8B Net income, FY2017: 256M Revenue, FY2018: 7.2B Net income, FY2018: -227M Revenue, FY2019: 7.5B Net income, FY2019: -656M Revenue, FY2020: 6.8B Net income, FY2020: -531M Revenue, FY2021: 8.3B Net income, FY2021: 376M Revenue, FY2022: 8.7B Net income, FY2022: 335M Revenue, FY2023: 9.5B Net income, FY2023: 974M Revenue, FY2024: 9.9B Net income, FY2024: 1B Revenue, FY2025: 10.4B Net income, FY2025: 980M FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue — $6.79B $7.15B $7.51B $6.83B $8.29B $8.72B $9.46B $9.91B $10.40B
Gross profit — — — — — — — — — —
Net income — $256.0M -$227.0M -$656.0M -$531.0M $376.0M $335.0M $974.0M $1.02B $980.0M

Others in SIC 3851

TickerCompanyMarket capP/ERevenue growth
COO COOPER COMPANIES, INC. $11.94B 32.7x 5.1%
BLCO Bausch & Lomb Corp $6.24B — 6.5%
WRBY Warby Parker Inc. $3.21B 2,591.0x 13.0%
EYE National Vision Holdings, Inc. $1.48B 50.5x 9.0%
STAA STAAR SURGICAL CO $1.13B — -23.7%
RXST RxSight, Inc. $208.8M — -3.9%
LUCY Innovative Eyewear Inc $7.5M — 62.6%